<DOC>
	<DOCNO>NCT02711852</DOCNO>
	<brief_summary>This long-term , continue treatment study evaluate long-term safety duvelisib patient hematologic malignancy previously treat duvelisib previous sponsor-approved study .</brief_summary>
	<brief_title>A Long-term , Continued Treatment Follow-up Study Subjects With Hematologic Malignancies Treated With Duvelisib ( IPI-145 )</brief_title>
	<detailed_description>Study IPI-145-23 international , multicenter , open-label , single-arm , Phase 2 study design evaluate long-term safety , clinical activity overall survival data duvelisib patient hematologic malignancy . Only subject participate previous duvelisib study approve sponsor allow enroll study . Enrollment undetermined multiple duvelisib study allow rollover active subject Verastem 's approval . Subjects active treatment subject survival follow-up allow rollover study . For subject active treatment , subject continue dose previous duvelisib study take duvelisib twice daily ( BID ) 28 day continuous cycle disease progression unacceptable toxicity . For subject survival follow-up , subject continue follow survival study duration outline previous duvelisib study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have participate previous study duvelisib , : Be actively receive duvelisib monotherapy previous study ( within 14 day study entry ) demonstrate clinical benefit ( complete response [ CR ] / partial response [ PR ] / stable disease [ SD ] ) continue use , Be survival followup phase previous duvelisib study Have complete required component previous study appropriate enrollment longterm continue treatment followup study , determine Sponsor Subjects actively receive duvelisib exclude study ongoing â‰¥ Grade 3 AE consider related duvelisib treatment screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>